CClinicalTrials.gg
CompletedNCT03657511Updated May 6, 2022

Tobacco Cessation Intervention

An interventional study of Educational Interventions to Promote Tobacco Cessation in Smoking Tobacco, sponsored by Barbara Ann Karmanos Cancer Institute. Completed at 1 site in United States. Open to female participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by Barbara Ann Karmanos Cancer Institute · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
21 Years and older
Sex
Female
01

Study summary

This study is planned as an evaluation of a low cost, simple smoking cessation intervention. There is very little information about the effectiveness of a simple tobacco cessation strategy. Therefore, our objective is to obtain estimates of effectiveness that can be used to refine existing programs or to develop new ones.

02

Conditions studied

  • Smoking Tobacco

Keywords

  • Smoking
03

In context

Lead sponsor

Barbara Ann Karmanos Cancer Institute is the lead sponsor of 158 studies on the registry; 19 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Able to understand and read English

Exclusion criteria

Exclusion Criteria:

  • Currently undergoing tobacco cessation treatment
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Other
    Educational Interventions to Promote Tobacco Cessation

    Behavioral: Educational Interventions to Promote Tobacco Cessation

Interventions

  • BehavioralEducational Interventions to Promote Tobacco Cessation

    Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in. Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks.

06

What researchers measure

Primary outcomes

  1. The number of women who quit smoking in the last 12 weeks

    Completion of second questionnaire to determine if participant is currently smoking or had quit smoking in the last 12 weeks.

    Time frame: 12 weeks after initial self-administered questionnaire

Secondary outcomes

  1. The number of women who attempted to quit smoking in the last 12 weeks.

    Completion of second questionnaire to determine if participant is currently smoking or had quit smoking in the last 12 weeks.

    Time frame: 12 weeks after initial self-administered questionnaire

07

Study locations

1 site
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03657511
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Responsible party
Ann Schwartz (Principal Investigator, Barbara Ann Karmanos Cancer Institute) — Principal investigator
First posted
Sep 5, 2018
Start date
Oct 22, 2018
Primary completion
Jun 21, 2021
Completion
Jun 21, 2021
Last update
May 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion